Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Sustained disease control at 12 weeks has improved to 80% Consistent anti-tumor activity, >75% of patients experiencing tumor shrinkage in target lesions Continued good safety and tolerability profile. Longest running patient still on treatment after 16 months with sustained partial…